Financial News

Sanofi 4Q Results

Revenues up 7% in the quarter despite €801 million loss.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sanofi

Sanofi 4Q Revenues: €11.3 billion +7% 4Q Loss: €801 million -261% FY Revenues: €43.6 billion +6% FY Earnings:  €7.8 billion +41% Comments: Dupixent sales were €4.2 billion in the quarter, up 32%. Lantus sales were €419 million, up 1%. Toujeo sales were €332 million, up 19%. Fabrazyme sales were €252 million, down 1%. Plavix sales were up 7.6% to €214 million in the quarter. Lovenox sales were $179 million, down 21.6% impacted by increasing competition...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters